DALLAS , Sept. 19, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, today announced presentations at the 24 th Euretina congress taking place on September 19 th -22 nd in Barcelona, Spain .
Details for the presentations are as follows: Title: Longitudinal AUC analysis of BCVA in patients treated with low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 100-week TOPLINE results from a Phase 2b /3 randomized, sham-controlled clinical trial (RESTORE) Session Date: September 21, 2024 Session Time: 9:36 am CEST Location: 115, Barcelona International Convention Center Presenter: Jordi Monés, MD, PhD, Director of Institut de la Màcula, and Barcelona Macula Foundation ( Spain ) In addition to typical measures of efficacy at single time points (primary and key secondary endpoints), Dr. Monés will present the efficacy analysis for best corrected visual acuity (BCVA) in Multi-Characteristic Opsin (MCO-010) treated retinitis pigmentosa patients using the area under the curve (AUC) method that captures treatment benefit over the entire 2-year observation period in RESTORE. Prof.
Jordi Monés ( Spain ) will also chair a satellite symposium focused on optogenetics therapeutics for IRDs and geographic atrophy. Details of the symposium are as follows. Symposium Title: Optogenetic Therapies.